Egis To Rival Richter In Biosimilars Market

Hungarian generics firm Egis has acquired distribution rights for biosimilar products from South Korean biotechnology company Celltrion across markets in Central and Eastern Europe (CEE), including the Commonwealth of Independent States (CIS). The deal includes eight unspecified biosimilar products, with exclusive marketing rights in the five largest CIS countries, in addition to non-exclusive distribution in 12 additional countries in the region. BMI believes the deal has strong potential, but marks a different strategy from domestic rival Gedeon

To read the full article, please choose one of the following options: